Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Granules now has a total of 67 ANDA approvals from the USFDA
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Subscribe To Our Newsletter & Stay Updated